LL-37
Host-defense antimicrobial peptide — research use; not an FDA consumer drug.
What it's for
LL-37 is a human cathelicidin peptide the immune system can make to help fight microbes and shape inflammation.
What it does for the body
Research explores infections, wound settings, and inflammatory disease models. It is not an approved over-the-counter antimicrobial peptide drug for general use. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
It can disrupt microbe membranes and gently adjust immune signaling. Think of a natural antiseptic signal the body already knows — powerful enough that unsupervised use raises safety questions.
Research context
Bottom line for readers: LL-37 is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Immune research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: LL-37 — FDA.gov search
- ClinicalTrials.gov search: LL-37 — U.S. clinical trials registry
- Drugs@FDA search: LL-37 — FDA drug database (if approved)
- PubMed search: LL-37 — NCBI PubMed
- PubMed Central search: LL-37 — NCBI PMC
Reference
No ref on file.